← Back to All US Stocks

SANUWAVE Health, Inc. (SNWV) Fundamental Analysis & AI Grade 2026

SNWV Nasdaq Surgical & Medical Instruments & Apparatus NV CIK: 0001417663
Updated This Month • Analysis: May 13, 2026 • SEC Data: 2026-03-31
Combined AI Grade
C
72% Confidence
N/A
C
72% Conf
Pending
Analysis scheduled

📊 SNWV Key Takeaways

Revenue: $9.6M
Net Margin: -15.0%
Free Cash Flow: $374.0K
Current Ratio: 1.31x
Debt/Equity: 11.16x
EPS: $-0.17
AI Grade: C with 72% confidence
SANUWAVE Health, Inc. (SNWV) receives a C fundamental grade with 72% confidence from our AI analysis based on SEC 10-K filings. With revenue of $9.6M, net profit margin of -15.0%, and return on equity (ROE) of -78.3%, SANUWAVE Health, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete SNWV stock analysis for 2026.

Is SANUWAVE Health, Inc. (SNWV) a Good Investment?

Claude

SANUWAVE demonstrates impressive revenue growth (+35% YoY) and exceptional gross margins (77.3%), indicating strong market demand and operational efficiency. However, these strengths are severely undermined by persistent unprofitability (-$1.4M net loss), unsustainable leverage (11.16x debt-to-equity), and inability to service debt from operations (negative 2.1x interest coverage), creating material default risk despite positive free cash flow.

SANUWAVE Health, Inc. Key Strengths (SNWV)

Claude
  • + Strong revenue growth of 35% YoY demonstrating significant market traction
  • + Exceptional gross margin of 77.3% indicating strong pricing power and efficient production
  • + Positive free cash flow of $374K despite operating losses shows disciplined working capital management
  • + Cash position of $10.8M provides near-term operational runway

SNWV Stock Risks: SANUWAVE Health, Inc. Investment Risks

Claude
  • ! Dangerously high leverage with debt-to-equity of 11.16x and long-term debt of $20.5M versus only $1.8M stockholders' equity creates insolvency risk
  • ! Cannot cover interest payments from operations (negative 2.1x interest coverage) indicating potential covenant violations or refinancing pressure
  • ! Operating margin deeply negative at -11.7% shows SG&A and R&D expenses are not controlled relative to revenue scale
  • ! Tight liquidity with quick ratio of 0.99x leaves minimal margin for error
  • ! Company remains unprofitable with net loss of $1.4M despite strong revenue, suggesting path to profitability unclear

Key Metrics to Watch

Claude
  • * Operating margin trajectory - must improve significantly to justify debt load; target positive operating income within 2-3 quarters
  • * Debt reduction progress - monitor long-term debt levels and refinancing activity; watch for debt covenant compliance disclosures
  • * Operating cash flow sustainability - verify if positive OCF of $397K can be maintained and expanded as revenue scales

SANUWAVE Health, Inc. (SNWV) Financial Metrics & Key Ratios

Revenue
$9.6M
Net Income
$-1.4M
EPS (Diluted)
$-0.17
Free Cash Flow
$374.0K
Total Assets
$37.1M
Cash Position
$10.8M

💡 AI Analyst Insight

The relatively thin 3.9% FCF margin may limit capital allocation flexibility.

SNWV Profit Margin, ROE & Profitability Analysis

Gross Margin 77.3%
Operating Margin -11.7%
Net Margin -15.0%
ROE -78.3%
ROA -3.9%
FCF Margin 3.9%

SNWV vs Healthcare Sector: How SANUWAVE Health, Inc. Compares

How SANUWAVE Health, Inc. compares to Healthcare sector averages

Net Margin
SNWV -15.0%
vs
Sector Avg 12.0%
SNWV Sector
ROE
SNWV -78.3%
vs
Sector Avg 15.0%
SNWV Sector
Current Ratio
SNWV 1.3x
vs
Sector Avg 2.0x
SNWV Sector
Debt/Equity
SNWV 11.2x
vs
Sector Avg 0.6x
SNWV Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is SANUWAVE Health, Inc. Stock Overvalued? SNWV Valuation Analysis 2026

Based on fundamental analysis, SANUWAVE Health, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.

Return on Equity
-78.3%
Sector avg: 15%
Net Profit Margin
-15.0%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
11.16x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

SANUWAVE Health, Inc. Balance Sheet: SNWV Debt, Cash & Liquidity

Current Ratio
1.31x
Quick Ratio
0.99x
Debt/Equity
11.16x
Debt/Assets
95.0%
Interest Coverage
-2.06x
Long-term Debt
$20.5M

SNWV Revenue & Earnings Growth: 5-Year Financial Trend

SNWV 5-year financial data: Year 2020: Revenue $4.1M, Net Income N/A, EPS N/A. Year 2021: Revenue $11.4M, Net Income -$30.9M, EPS $-0.08. Year 2022: Revenue $15.5M, Net Income -$27.3M, EPS $-0.05. Year 2023: Revenue $19.3M, Net Income -$10.3M, EPS $-0.02. Year 2024: Revenue $32.3M, Net Income -$25.8M, EPS $-12.19.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: SANUWAVE Health, Inc.'s revenue has grown significantly by 697% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.

SNWV Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
3.9%
Free cash flow / Revenue

SNWV Quarterly Earnings & Performance

Quarterly financial performance data for SANUWAVE Health, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $9.3M $5.7M $0.38
Q2 2025 $7.1M $1.1M $0.01
Q1 2025 $5.7M -$4.5M $-0.66
Q3 2024 $4.8M -$18.6M $-5.92
Q2 2024 $4.4M $2.0M $0.00
Q1 2024 $3.5M -$4.5M $0.00
Q3 2023 $3.9M -$1.1M $0.00
Q2 2023 $3.5M $1.6M $0.00

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

SANUWAVE Health, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
$397.0K
Cash generated from operations
Capital Expenditures
$23.0K
Investment in assets
Dividends
None
No dividend program

SNWV SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for SANUWAVE Health, Inc. (CIK: 0001417663)

📋 Recent SEC Filings

Date Form Document Action
May 12, 2026 8-K snwv-20260512.htm View →
May 12, 2026 10-Q snwv-20260331.htm View →
May 4, 2026 4 xslF345X06/ownership.xml View →
Apr 30, 2026 4 xslF345X06/ownership.xml View →
Apr 29, 2026 DEF 14A ny20069896x1_def14a.htm View →

Frequently Asked Questions about SNWV

What is the AI rating for SNWV?

SANUWAVE Health, Inc. (SNWV) has an AI grade of C with 72% confidence, based on fundamental analysis of SEC EDGAR filings.

What are SNWV's key strengths?

Claude: Strong revenue growth of 35% YoY demonstrating significant market traction. Exceptional gross margin of 77.3% indicating strong pricing power and efficient production.

What are the risks of investing in SNWV?

Claude: Dangerously high leverage with debt-to-equity of 11.16x and long-term debt of $20.5M versus only $1.8M stockholders' equity creates insolvency risk. Cannot cover interest payments from operations (negative 2.1x interest coverage) indicating potential covenant violations or refinancing pressure.

What is SNWV's revenue and growth?

SANUWAVE Health, Inc. reported revenue of $9.6M.

Does SNWV pay dividends?

SANUWAVE Health, Inc. does not currently pay dividends.

Where can I find SNWV SEC filings?

Official SEC filings for SANUWAVE Health, Inc. (CIK: 0001417663) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is SNWV's EPS?

SANUWAVE Health, Inc. has a diluted EPS of $-0.17.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is SNWV's fundamental grade?

Based on our AI fundamental analysis in June 2026, SANUWAVE Health, Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is SNWV stock overvalued or undervalued?

Valuation metrics for SNWV: ROE of -78.3% (sector avg: 15%), net margin of -15.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is SNWV's AI grade for 2026?

Our dual AI analysis gives SANUWAVE Health, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is SNWV's free cash flow?

SANUWAVE Health, Inc.'s operating cash flow is $397.0K, with capital expenditures of $23.0K. FCF margin is 3.9%.

How does SNWV compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -15.0% (avg: 12%), ROE -78.3% (avg: 15%), current ratio 1.31 (avg: 2).

Is SANUWAVE Health, Inc. carrying too much debt?

SNWV has a debt-to-equity ratio of 11.16x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.31 suggests adequate short-term liquidity.

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% AVGO 87% DECK 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 13, 2026 | Data as of: 2026-03-31 | Powered by Claude AI